Yelak Biru Phase 3 trials

Yelak Biru: Ongoing development of novel drugs and innovative combinations is key to pursuing a cure

Yelak Biru, President and Chief Executive Officer of International Myeloma Foundation, shared a post on X a paper by Susan Bal published in The Lancet Haematology:

“Monumen-TAL progress in the treatment of relapsed multiple myeloma – Ongoing drug development of novel agents and deployment of innovative combinations remains paramount in chasing the elusive cure.”

“Monumen-TAL progress in the treatment of relapsed multiple myeloma”

Author: Susan Bal.

Yelak Biru: Ongoing development of novel drugs and innovative combinations is key to pursuing a cure

More posts featuring Yelak Biru.